Patents by Inventor Holbrook Kohrt

Holbrook Kohrt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions comprising chemerin and methods of use thereof
    Patent number: 11938193
    Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 26, 2024
    Assignee: Washington University
    Inventors: Russell Pachynski, Holbrook Kohrt, Jason Yonehiro, Brian Zabel
  • COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF
    Publication number: 20240075155
    Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
    Type: Application
    Filed: May 2, 2023
    Publication date: March 7, 2024
    Inventors: Russell Pachynski, Holbrook Kohrt, Jason Yonehiro, Brian Zabel
  • TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY
    Publication number: 20200397895
    Abstract: Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor.
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: Ronald Levy, Betty Chang, Patrick Ng, Idit Sagiv-Barfi, Holbrook Kohrt
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF
    Publication number: 20190008982
    Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
    Type: Application
    Filed: January 9, 2017
    Publication date: January 10, 2019
    Inventors: Russell PACHYNSKI, Holbrook KOHRT, Jason YONEHIRO, Brian ZABEL
  • METHODS FOR ENHANCING ANTI-TUMOR ANTIBODY THERAPY
    Publication number: 20180208670
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Application
    Filed: August 4, 2017
    Publication date: July 26, 2018
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 9758589
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: September 12, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • MEDICAL USES OF CRTAM AGONISTS
    Publication number: 20170022286
    Abstract: Methods and compositions relating to use of CRTAM agonists are provided. In some embodiments, the present invention provides methods and compositions relating to use of CRTAM in the treatment of cancer, including enhancing the efficacy of antibody therapy directed to cancer cells.
    Type: Application
    Filed: March 23, 2016
    Publication date: January 26, 2017
    Inventor: Holbrook Kohrt
  • MEDICAL USES OF CD38 AGONISTS
    Publication number: 20160235842
    Abstract: Methods and compositions relating to medical (e.g., therapeutic) use of CD38 agonists are provided. In some embodiments, the present invention provides methods and compositions relating to use of CD38 in the treatment of cancer, particularly to enhance the efficacy of antibody therapy directed to cancer cells.
    Type: Application
    Filed: July 15, 2014
    Publication date: August 18, 2016
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew J. Goldstein, Ronald Levy, Holbrook Kohrt
  • Methods for Enhancing Anti-Tumor Antibody Therapy
    Publication number: 20160083474
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 24, 2016
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY
    Publication number: 20150118222
    Abstract: Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventors: Ronald LEVY, Betty CHANG, Patrick NG, Idit SAGIV-BARFI, Holbrook KOHRT
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 9005619
    Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: April 14, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for Enhancing Anti-Tumor Antibody Therapy
    Publication number: 20120321646
    Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.
    Type: Application
    Filed: December 7, 2010
    Publication date: December 20, 2012
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Immune profiling of lymph nodes associated with cancer
    Publication number: 20070048803
    Abstract: Cancers are phenotyped by analysis of the presence of immune cells, particularly T cells and dendritic cells, present in regional lymph nodes. When non-sentinel regional lymph nodes of a cancer patient are compared to normal lymph nodes, it is found that increased number of dendritic cells and decreased numbers of T cells, particularly T helper cells, correlate with a positive prognosis and disease-free survival following conventional chemotherapy.
    Type: Application
    Filed: August 25, 2006
    Publication date: March 1, 2007
    Inventors: Peter Lee, Holbrook Kohrt, Susan Holmes